CABA
Cabaletta Bio, Inc.
Price Chart
Latest Quote
$2.84
+0.00 (+0.00%)
Current Price
| Previous Close | $2.84 |
| Open | $2.93 |
| Day High | $2.96 |
| Day Low | $2.83 |
| Volume | 17,176,327 |
Stock Information
| Shares Outstanding | 163.05M |
| Total Debt | $26.45M |
| Cash Equivalents | $116.64M |
| Net Income | $-175.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $463.08M |
| EPS (TTM) | $-1.78 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $366.37M |
| Income | $-175.43M |
| Book/sh | $0.93 |
| Cash/sh | $0.72 |
| Employees | 156 |
Financial Ratios
| Quick Ratio | 2.81 |
| Current Ratio | 2.95 |
| Debt/Eq | 25.60 |
Returns & Margins
| ROA | -71.58% |
| ROE | -156.03% |
Ownership
| Insider Ownership | 1.00% |
| Institutional Ownership | 63.64% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.00 |
| P/B | 3.06 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $13.38 |
Technical Indicators
| SMA20 | $3.35 |
| SMA50 | $3.36 |
| SMA200 | $2.75 |
| RSI | 6.48 |
| ATR | 0.2596 |
| Shares Float | 142.90M |
| Short Float | 15.57% |
| Short Ratio | 4.56 |
| Volatility | 3.23 |
| Rel Volume | 4.00 |
Performance History
| Week | -5.65% |
| Month | -13.15% |
| Quarter | -6.58% |
| 6 Months | +18.83% |
| YTD | +28.51% |
| Year | +52.28% |
| 3 Years | -77.51% |
| 5 Years | -66.82% |
| 10 Years | -71.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.84 | 17,176,500 |
| 2026-06-17 | $2.84 | 5,139,500 |
| 2026-06-16 | $2.80 | 6,157,100 |
| 2026-06-15 | $3.01 | 3,241,700 |
| 2026-06-12 | $3.01 | 2,913,400 |
| 2026-06-11 | $3.01 | 3,127,200 |
| 2026-06-10 | $3.04 | 2,901,600 |
| 2026-06-09 | $3.22 | 4,551,500 |
| 2026-06-08 | $3.20 | 2,977,600 |
| 2026-06-05 | $3.25 | 4,288,000 |
| 2026-06-04 | $3.51 | 3,825,900 |
| 2026-06-03 | $3.58 | 4,646,300 |
| 2026-06-02 | $3.68 | 3,441,700 |
| 2026-06-01 | $3.67 | 2,714,600 |
| 2026-05-29 | $3.78 | 2,536,100 |
| 2026-05-28 | $3.77 | 2,621,600 |
| 2026-05-27 | $3.83 | 5,350,800 |
| 2026-05-26 | $3.72 | 2,414,300 |
| 2026-05-22 | $3.65 | 2,242,900 |
| 2026-05-21 | $3.69 | 3,601,400 |
| 2026-05-20 | $3.44 | 3,290,900 |
| 2026-05-19 | $3.27 | 2,753,700 |
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
đ° Latest News
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup
Insider Monkey âĸ 2026-06-17T15:16:44Z
FDA Clears Imvivaâs Dual-Target CAR-T for Autoimmune Diseases
Exec Edge âĸ 2026-06-09T21:19:19Z
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
Insider Monkey âĸ 2026-06-07T17:58:54Z
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-05-20T13:40:05Z
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Zacks âĸ 2026-05-18T16:00:05Z
This Biotech Stock Could Deliver 350% Returns in 12 Months
GuruFocus.com âĸ 2026-03-27T17:11:27ZCabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference
MarketBeat âĸ 2026-03-07T10:46:41Z
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-03-06T17:00:05Z
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Zacks âĸ 2026-03-03T14:40:02Z
Hereâs Why Jacob Funds Established a Position in Cabaletta Bio (CABA)
Insider Monkey âĸ 2026-02-18T13:34:41Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $2,004,000 | $748,000 | $0 | - |
| Total Expenses | $172,241,000 | $125,141,000 | $74,660,000 | $54,139,000 |
| Other Income Expense | $358,000 | - | - | - |
| Other Non Operating Income Expenses | $358,000 | - | - | - |
| Net Non Operating Interest Income Expense | $4,027,000 | $9,277,000 | $6,985,000 | $1,164,000 |
| Interest Expense Non Operating | $2,004,000 | $748,000 | $0 | - |
| Operating Expense | $172,241,000 | $125,141,000 | $74,660,000 | $54,139,000 |
| General And Administrative Expense | $29,567,000 | $27,938,000 | $19,236,000 | $14,839,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Net Interest Income | $4,027,000 | $9,277,000 | $6,985,000 | $1,164,000 |
| Interest Income | $6,031,000 | $10,025,000 | $6,985,000 | $1,164,000 |
| Normalized Income | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Net Income From Continuing And Discontinued Operation | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Total Operating Income As Reported | $-172,241,000 | $-125,141,000 | $-74,660,000 | $-54,139,000 |
| Net Income Common Stockholders | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Net Income | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Net Income Including Noncontrolling Interests | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Net Income Continuous Operations | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Pretax Income | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Interest Income Non Operating | $6,031,000 | $10,025,000 | $6,985,000 | $1,164,000 |
| Operating Income | $-172,241,000 | $-125,141,000 | $-74,660,000 | $-54,139,000 |
| Per Share | ||||
| Diluted EPS | $-2.10 | $-2.34 | $-1.65 | $-1.81 |
| Basic EPS | $-2.10 | $-2.34 | $-1.65 | $-1.81 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-164,206,000 | $-113,405,000 | $-66,249,000 | $-52,961,000 |
| Reconciled Depreciation | $1,646,000 | $1,711,000 | $1,426,000 | $1,178,000 |
| EBITDA (Bullshit earnings) | $-164,206,000 | $-113,405,000 | $-66,249,000 | $-52,961,000 |
| EBIT | $-165,852,000 | $-115,116,000 | $-67,675,000 | $-54,139,000 |
| Diluted Average Shares | $79,903,224 | $49,514,530 | $40,945,950 | $29,267,956 |
| Basic Average Shares | $79,903,224 | $49,514,530 | $39,192,445 | $29,267,956 |
| Diluted NI Availto Com Stockholders | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
| Research And Development | $142,674,000 | $97,203,000 | $55,424,000 | $39,300,000 |
| Selling General And Administration | $29,567,000 | $27,938,000 | $19,236,000 | $14,839,000 |
| Other Gand A | $29,567,000 | $27,938,000 | $19,236,000 | $14,839,000 |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $112,051,000 | $152,335,000 | $236,198,000 | $104,520,000 |
| Total Assets | $165,083,000 | $185,046,000 | $253,650,000 | $116,968,000 |
| Total Non Current Assets | $26,212,000 | $18,371,000 | $9,160,000 | $8,134,000 |
| Other Non Current Assets | $5,159,000 | $2,293,000 | $1,709,000 | $565,000 |
| Current Assets | $138,871,000 | $166,675,000 | $244,490,000 | $108,834,000 |
| Other Current Assets | $5,272,000 | $2,713,000 | $3,241,000 | $2,287,000 |
| Cash Cash Equivalents And Short Term Investments | $133,599,000 | $163,962,000 | $241,249,000 | $106,547,000 |
| Cash And Cash Equivalents | $82,982,000 | $163,962,000 | $193,238,000 | $81,607,000 |
| Cash Equivalents | $81,470,000 | - | $192,495,000 | $81,607,000 |
| Cash Financial | $1,512,000 | - | $743,000 | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $27,098,000 | $15,600,000 | $5,018,000 | $5,138,000 |
| Long Term Debt And Capital Lease Obligation | $2,879,000 | $5,625,000 | $1,458,000 | $2,959,000 |
| Current Debt And Capital Lease Obligation | $24,219,000 | $9,975,000 | $3,560,000 | $2,179,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,032,000 | $32,711,000 | $17,452,000 | $12,448,000 |
| Total Non Current Liabilities Net Minority Interest | $2,879,000 | $5,625,000 | $1,458,000 | $2,959,000 |
| Current Liabilities | $50,153,000 | $27,086,000 | $15,994,000 | $9,489,000 |
| Other Current Liabilities | $80,000 | $40,000 | $40,000 | $39,000 |
| Payables And Accrued Expenses | $16,138,000 | $8,756,000 | $7,194,000 | $3,756,000 |
| Payables | $6,636,000 | $4,923,000 | $4,547,000 | $2,463,000 |
| Accounts Payable | $6,636,000 | $4,923,000 | $4,547,000 | $2,463,000 |
| Equity | ||||
| Common Stock Equity | $112,050,000 | $152,334,000 | $236,198,000 | $104,520,000 |
| Preferred Stock Equity | $1,000 | $1,000 | - | - |
| Total Equity Gross Minority Interest | $112,051,000 | $152,335,000 | $236,198,000 | $104,520,000 |
| Stockholders Equity | $112,051,000 | $152,335,000 | $236,198,000 | $104,520,000 |
| Gains Losses Not Affecting Retained Earnings | $25,000 | $0 | $39,000 | $-47,000 |
| Other Equity Adjustments | $25,000 | - | $39,000 | $-47,000 |
| Retained Earnings | $-516,957,000 | $-349,101,000 | $-233,237,000 | $-165,562,000 |
| Other | ||||
| Ordinary Shares Number | $100,479,323 | $50,743,101 | $46,378,937 | $29,445,134 |
| Share Issued | $100,479,323 | $50,743,101 | $46,378,937 | $29,445,134 |
| Tangible Book Value | $112,050,000 | $152,334,000 | $236,198,000 | $104,520,000 |
| Invested Capital | $112,050,000 | $152,334,000 | $236,198,000 | $104,520,000 |
| Working Capital | $88,718,000 | $139,589,000 | $228,496,000 | $99,345,000 |
| Capital Lease Obligations | $27,098,000 | $15,600,000 | $5,018,000 | $5,138,000 |
| Total Capitalization | $112,051,000 | $152,335,000 | $236,198,000 | $104,520,000 |
| Additional Paid In Capital | $628,982,000 | $501,435,000 | $469,396,000 | $270,129,000 |
| Capital Stock | $1,000 | $1,000 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $1,000 | $1,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,879,000 | $5,625,000 | $1,458,000 | $2,959,000 |
| Current Capital Lease Obligation | $24,219,000 | $9,975,000 | $3,560,000 | $2,179,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,716,000 | $8,315,000 | $5,200,000 | $3,515,000 |
| Current Accrued Expenses | $9,502,000 | $3,833,000 | $2,647,000 | $1,293,000 |
| Net PPE | $21,053,000 | $16,078,000 | $7,451,000 | $7,569,000 |
| Accumulated Depreciation | $-7,152,000 | $-5,506,000 | $-3,795,000 | $-2,369,000 |
| Gross PPE | $28,205,000 | $21,584,000 | $11,246,000 | $9,938,000 |
| Leases | $113,000 | $113,000 | $113,000 | $113,000 |
| Other Properties | $27,619,000 | $20,998,000 | $10,803,000 | $9,495,000 |
| Machinery Furniture Equipment | $473,000 | $473,000 | $330,000 | $330,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $50,617,000 | $0 | $48,011,000 | $24,940,000 |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-132,309,000 | $-90,433,000 | $-54,236,000 | $-48,833,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-131,080,000 | $-88,222,000 | $-53,549,000 | $-46,380,000 |
| Cash Flow From Continuing Operating Activities | $-131,080,000 | $-88,222,000 | $-53,549,000 | $-46,380,000 |
| Operating Gains Losses | $225,000 | $38,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,229,000 | $-2,211,000 | $-687,000 | $-2,453,000 |
| Investing Cash Flow | $-50,266,000 | $47,289,000 | $-22,451,000 | $-27,217,000 |
| Cash Flow From Continuing Investing Activities | $-50,266,000 | $47,289,000 | $-22,451,000 | $-27,217,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $106,303,000 | $10,875,000 | $185,202,000 | $32,855,000 |
| Financing Cash Flow | $100,347,000 | $11,677,000 | $187,631,000 | $32,982,000 |
| Cash Flow From Continuing Financing Activities | $100,347,000 | $11,677,000 | $187,631,000 | $32,982,000 |
| Net Common Stock Issuance | $106,303,000 | $10,875,000 | $185,202,000 | $32,855,000 |
| Common Stock Issuance | $106,303,000 | $10,875,000 | $185,202,000 | $32,855,000 |
| Other | ||||
| Repayment Of Debt | $-6,261,000 | $-897,000 | $0 | - |
| Interest Paid Supplemental Data | $1,713,000 | $748,000 | $0 | - |
| End Cash Position | $82,982,000 | $163,962,000 | $193,238,000 | $81,607,000 |
| Beginning Cash Position | $163,962,000 | $193,238,000 | $81,607,000 | $122,222,000 |
| Effect Of Exchange Rate Changes | $19,000 | $-20,000 | $0 | - |
| Changes In Cash | $-80,999,000 | $-29,256,000 | $111,631,000 | $-40,615,000 |
| Proceeds From Stock Option Exercised | $305,000 | $1,699,000 | $2,429,000 | $127,000 |
| Net Issuance Payments Of Debt | $-6,261,000 | $-897,000 | $0 | - |
| Net Long Term Debt Issuance | $-6,261,000 | $-897,000 | $0 | - |
| Long Term Debt Payments | $-6,261,000 | $-897,000 | $0 | - |
| Net Investment Purchase And Sale | $-49,037,000 | $49,500,000 | $-21,764,000 | $-24,764,000 |
| Sale Of Investment | $50,000,000 | $49,500,000 | $62,500,000 | $25,000,000 |
| Purchase Of Investment | $-99,037,000 | $0 | $-84,264,000 | $-49,764,000 |
| Net PPE Purchase And Sale | $-1,229,000 | $-2,211,000 | $-687,000 | $-2,453,000 |
| Purchase Of PPE | $-1,229,000 | $-2,211,000 | $-687,000 | $-2,453,000 |
| Change In Working Capital | $-379,000 | $1,611,000 | $101,000 | $-4,299,000 |
| Change In Other Current Liabilities | $-4,227,000 | $-3,291,000 | $-2,456,000 | $-2,910,000 |
| Change In Other Current Assets | $-2,866,000 | $-584,000 | $-1,144,000 | $-208,000 |
| Change In Payables And Accrued Expense | $9,273,000 | $4,958,000 | $4,655,000 | $-1,213,000 |
| Change In Accrued Expense | $7,723,000 | $3,947,000 | $2,980,000 | $-1,185,000 |
| Change In Interest Payable | $291,000 | $0 | - | - |
| Change In Payable | $1,550,000 | $1,011,000 | $1,675,000 | $-28,000 |
| Change In Account Payable | $1,550,000 | $1,011,000 | $1,675,000 | $-28,000 |
| Change In Prepaid Assets | $-2,559,000 | $528,000 | $-954,000 | $32,000 |
| Other Non Cash Items | $15,900,000 | $6,345,000 | $2,478,000 | $3,042,000 |
| Stock Based Compensation | $20,939,000 | $19,465,000 | $11,343,000 | $6,897,000 |
| Amortization Of Securities | $-1,555,000 | $-1,528,000 | $-1,222,000 | $-223,000 |
| Depreciation Amortization Depletion | $1,646,000 | $1,711,000 | $1,426,000 | $1,178,000 |
| Depreciation And Amortization | $1,646,000 | $1,711,000 | $1,426,000 | $1,178,000 |
| Depreciation | $1,646,000 | $1,711,000 | $1,426,000 | $1,178,000 |
| Net Foreign Currency Exchange Gain Loss | $225,000 | $38,000 | $0 | - |
| Net Income From Continuing Operations | $-167,856,000 | $-115,864,000 | $-67,675,000 | $-52,975,000 |
Fetched: 2026-06-11